Quintiles has introduced Allume, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic and corporate control of their assets. Allume simplifies and organizes the complex and resource-intensive launch planning process, provides unique data-driven insights from market-entry experience across the globe and taps Quintiles’ local market and therapeutic category expertise.
“Biopharma companies are looking for new ways to optimize product value, expedite market access, mitigate commercialization risk, yet retain asset value, while reaching patients across diverse geographic regions,” said Dean Summerfield, vice president, consulting, at Quintiles. “To maximize value, they need to start planning product launch early in the drug development process, especially when preparing to enter new geographic markets.”
Allume combines consulting, clinical and commercial expertise with with state-of-the-art software, incorporating Quintiles’ biopharma product launch experience into support to complement in-house capabilities. It can be customized to each company and product to help identify key market challenges, fast-track launch rollout and efficiency in resource management.